SCHEMBL90894

SCHEMBL90894

O=C(Nc1cc(C(F)(F)F)cc[n+]1[O-])Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
FAAH O00519 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
MAPT P10636 4/20 0.43
CYP1A2 P05177 1/20 0.42
BCHE P06276 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 2/20 0.40
RAB9A P51151 2/20 0.40
THRB P10828 1/20 0.40
GFER P55789 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GAA P10253 3/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90891 0.88 CYP11B1 (0.42) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL879003 0.86 FAAH (0.44) ALDH1A1FAAHTRPV1MAPTCYP1A2
SCHEMBL2635687 0.81 TACR1 (0.42) ALDH1A1MAPTCYP1A2MEN1KMT2A
SCHEMBL10278822 0.78 CFTR (0.36) ALDH1A1MAPTCYP1A2MEN1KMT2A
SCHEMBL9599428 0.78 ALDH1A1 (0.47) ALDH1A1MAPTCYP1A2BCHEMEN1
SCHEMBL16907464 0.74 MAPT (0.66) ALDH1A1FAAHTRPV1MAPTCYP1A2
SCHEMBL2652670 0.74 P2RX1 (0.60) ALDH1A1FAAHTRPV1MAPTCYP1A2
SCHEMBL21319259 0.72 NPSR1 (0.57) ALDH1A1FAAHTRPV1MAPTCYP1A2
SCHEMBL13437385 0.72 NPC1 (0.57) ALDH1A1FAAHTRPV1MAPTMEN1
SCHEMBL27948244 0.72 ALDH1A1 (0.67) ALDH1A1FAAHTRPV1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957485-B1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2013-02-13 EP disclosed
US-8129379-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-06 US disclosed
US-20100179125-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179125-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS CDK4, CDKL4, MKI67 ALDH1A1 3325/4885FAAH 3872/4885TRPV1 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.